OS THERAPIES INC (OSTX) Fundamental Analysis & Valuation

NYSEARCA:OSTX • US68764Y2072

Current stock price

1.55 USD
+0.03 (+1.97%)
At close:
1.54 USD
-0.01 (-0.65%)
After Hours:

This OSTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. OSTX Profitability Analysis

1.1 Basic Checks

  • In the past year OSTX has reported negative net income.
  • In the past year OSTX has reported a negative cash flow from operations.
OSTX Yearly Net Income VS EBIT VS OCF VS FCFOSTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • With a Return On Assets value of -226.24%, OSTX is not doing good in the industry: 90.37% of the companies in the same industry are doing better.
  • The Return On Equity of OSTX (-430.26%) is worse than 74.95% of its industry peers.
Industry RankSector Rank
ROA -226.24%
ROE -430.26%
ROIC N/A
ROA(3y)-813.87%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OSTX Yearly ROA, ROE, ROICOSTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

  • OSTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OSTX Yearly Profit, Operating, Gross MarginsOSTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. OSTX Health Analysis

2.1 Basic Checks

  • OSTX has more shares outstanding than it did 1 year ago.
  • OSTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
OSTX Yearly Shares OutstandingOSTX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M
OSTX Yearly Total Debt VS Total AssetsOSTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 5M 10M

2.2 Solvency

  • OSTX has an Altman-Z score of -8.34. This is a bad value and indicates that OSTX is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -8.34, OSTX is doing worse than 69.36% of the companies in the same industry.
  • There is no outstanding debt for OSTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.34
ROIC/WACCN/A
WACCN/A
OSTX Yearly LT Debt VS Equity VS FCFOSTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

  • A Current Ratio of 0.56 indicates that OSTX may have some problems paying its short term obligations.
  • OSTX has a Current ratio of 0.56. This is amonst the worse of the industry: OSTX underperforms 90.17% of its industry peers.
  • OSTX has a Quick Ratio of 0.56. This is a bad value and indicates that OSTX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.56, OSTX is doing worse than 89.60% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.56
Quick Ratio 0.56
OSTX Yearly Current Assets VS Current LiabilitesOSTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. OSTX Growth Analysis

3.1 Past

  • The earnings per share for OSTX have decreased strongly by -174.65% in the last year.
EPS 1Y (TTM)-174.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 13.92% on average over the next years. This is quite good.
  • OSTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 247.07% yearly.
EPS Next Y35.31%
EPS Next 2Y26.29%
EPS Next 3Y22.71%
EPS Next 5Y13.92%
Revenue Next Year-100%
Revenue Next 2Y771.98%
Revenue Next 3Y445.88%
Revenue Next 5Y247.07%

3.3 Evolution

OSTX Yearly Revenue VS EstimatesOSTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
OSTX Yearly EPS VS EstimatesOSTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

1

4. OSTX Valuation Analysis

4.1 Price/Earnings Ratio

  • OSTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OSTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OSTX Price Earnings VS Forward Price EarningsOSTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OSTX Per share dataOSTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as OSTX's earnings are expected to grow with 22.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.29%
EPS Next 3Y22.71%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. OSTX Dividend Analysis

5.1 Amount

  • No dividends for OSTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

OSTX Fundamentals: All Metrics, Ratios and Statistics

OS THERAPIES INC

NYSEARCA:OSTX (3/13/2026, 8:04:00 PM)

After market: 1.54 -0.01 (-0.65%)

1.55

+0.03 (+1.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)04-06
Inst Owners5.07%
Inst Owner Change19.04%
Ins Owners14.31%
Ins Owner Change0%
Market Cap54.58M
Revenue(TTM)N/A
Net Income(TTM)-20.26M
Analysts82
Price Target13.01 (739.35%)
Short Float %5.41%
Short Ratio2.52
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-63.34%
Min EPS beat(2)-64.71%
Max EPS beat(2)-61.98%
EPS beat(4)0
Avg EPS beat(4)-96.24%
Min EPS beat(4)-194.12%
Max EPS beat(4)-61.98%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.86%
EPS NY rev (1m)1.15%
EPS NY rev (3m)1.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 11.59
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.88
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0
BVpS0.13
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -226.24%
ROE -430.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-813.87%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.56
Quick Ratio 0.56
Altman-Z -8.34
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-174.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y35.31%
EPS Next 2Y26.29%
EPS Next 3Y22.71%
EPS Next 5Y13.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y771.98%
Revenue Next 3Y445.88%
Revenue Next 5Y247.07%
EBIT growth 1Y-293.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-142.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-142.18%
OCF growth 3YN/A
OCF growth 5YN/A

OS THERAPIES INC / OSTX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for OS THERAPIES INC?

ChartMill assigns a fundamental rating of 2 / 10 to OSTX.


Can you provide the valuation status for OS THERAPIES INC?

ChartMill assigns a valuation rating of 1 / 10 to OS THERAPIES INC (OSTX). This can be considered as Overvalued.


How profitable is OS THERAPIES INC (OSTX) stock?

OS THERAPIES INC (OSTX) has a profitability rating of 0 / 10.


How financially healthy is OS THERAPIES INC?

The financial health rating of OS THERAPIES INC (OSTX) is 4 / 10.


What is the expected EPS growth for OS THERAPIES INC (OSTX) stock?

The Earnings per Share (EPS) of OS THERAPIES INC (OSTX) is expected to grow by 35.31% in the next year.